ARTICLE | Product Development
Spinout's gamble on Xigris
Lilly spinout BioCritica gambles that Phase III data will re-energize Xigris
June 13, 2011 7:00 AM UTC
Eli Lilly and Co. spinout BioCritica Inc. and its investors are betting that new data on sepsis drug Xigris drotrecogin alfa can increase the drug's use, reversing a negative sales trend.
Lilly, NovaQuest Capital and Care Capital formed the newco last month, providing it with an undisclosed investment and an exclusive license to Xigris in the U.S. BioCritica also has options to license Xigris in the rest of the world and to undisclosed preclinical critical care candidates from Lilly...